YTHDF2 Regulates Cell Growth and Cycle by Facilitating KDM1A mRNA Stability

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Breast cancer remains a leading cause of cancer mortality in women.
• N6-methyladenosine (m6A) methylation's role in cancer is an emerging research area.
• Investigating m6A regulators is crucial for understanding cancer development.

Purpose of the Study:

• To identify key N6-methyladenosine genes involved in breast cancer.
• To elucidate the functional role of YTHDF2 and its interaction with KDM1A in breast cancer progression.
• To explore potential therapeutic targets for breast cancer treatment.

Main Methods:

• Analysis of four public breast cancer datasets (GSE70947, GSE45827, GSE42586, TCGA).
• In vitro experiments assessing cell proliferation, cell cycle, and invasion.
• Xenograft nude mouse models for tumorigenesis studies.
• Correlation analysis and mRNA stability assays.

Main Results:

• YTHDF2 was highly expressed in breast cancer tissues and cells, correlating positively with KDM1A.
• YTHDF2 knockdown inhibited proliferation, cell cycle progression, and invasion in vitro and reduced tumor formation in vivo.
• YTHDF2 knockdown decreased KDM1A expression and KDM1A mRNA methylation levels.
• YTHDF2 promotes KDM1A mRNA stability, thereby enhancing breast cancer cell growth and progression.

Conclusions:

• YTHDF2 drives breast cancer progression by stabilizing KDM1A mRNA.
• The YTHDF2/KDM1A axis represents a promising therapeutic target for breast cancer.
• Further research into m6A modification in breast cancer is warranted.